Novo Nordisk received FDA approval for oral Wegovy, but unit economics are structurally unfavorable due to poor bioavailability and high API requirements. I cut my rating to Sell (market underperform) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback